Royalty Pharma plcRPRXNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank85
3Y CAGR-4.8%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-4.8%/yr
Quarterly compound
Percentile
P85
Within normal range
vs 3Y Ago
0.9x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 38.35% |
| Q3 2025 | -33.95% |
| Q2 2025 | 62.39% |
| Q1 2025 | 63.79% |
| Q4 2024 | 19.17% |
| Q3 2024 | 3.68% |
| Q2 2024 | -5.11% |
| Q1 2024 | -2.59% |
| Q4 2023 | 3.41% |
| Q3 2023 | 20.15% |
| Q2 2023 | -44.41% |
| Q1 2023 | 17.02% |
| Q4 2022 | 44.46% |
| Q3 2022 | -2.22% |
| Q2 2022 | 0.59% |
| Q1 2022 | 11.65% |
| Q4 2021 | -5.00% |
| Q3 2021 | 8.16% |
| Q2 2021 | 4.09% |
| Q1 2021 | -13.89% |
| Q4 2020 | -1.21% |
| Q3 2020 | 18.54% |
| Q2 2020 | 12.44% |
| Q1 2020 | 65.06% |
| Q4 2019 | -9.93% |
| Q3 2019 | -15.64% |
| Q2 2019 | 24.25% |
| Q1 2019 | 0.00% |